title: BRAF(V600E) mutation and the biology of papillary thyroid cancer.
abstract: BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers. We evaluated the relationship between BRAF((V600E)) and tumor, host, and environmental factors in PTCs from all geographical areas of Sicily. By PCR, BRAF((V600E)) was investigated in a series of 323 PTCs diagnosed in 2002-2005. The correlation between clinicopathological tumor, host, and environmental characteristics and the presence of BRAF((V600E)) were evaluated by both univariate and multivariate analyses. BRAF((V600E)) was found in 38.6% PTCs, with a 52% frequency in the classical PTCs and 26.4% in the tall cell variant. Univariate analysis indicated that BRAF((V600E)) was associated with greater tumor size (P=0.0048), extra-thyroid invasion (P<0.0001), and cervical lymph nodal metastases (P=0.0001). Multivariate logistic regression analysis confirmed that BRAF((V600E)) was an independent predictor of extra-thyroid invasion (P=0.0001) and cervical lymph nodal metastasis (P=0.0005). The association between BRAF((V600E)) and extra-thyroid invasion was also found in micro-PTCs (P=0.006). In 60 classical PTCs, BRAF((V600E)) was positively correlated with matrix metalloproteinase-9 expression (P=0.0047), suggesting a possible mechanism for BRAF((V600E)) effect on PTC invasiveness. No association was found between BRAF((V600E)) and patient age, gender, or iodine intake. In contrast, a strong association was found with residency in Eastern Sicily (P<0.0001 compared with Western Sicily). These results indicate that BRAF((V600E)) mutation is a marker of aggressive disease in both micro- and macro-PTCs. Moreover, for the first time, a possible link between BRAF((V600E)) mutation and environmental carcinogens is suggested.
authors.affiliation: Endocrinologia, Dipartimento di Medicina Interna e Medicina Specialistica, University of Catania, PO Garibaldi Nesima, Via Palermo 636, Catania, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Frasca
authors.forename: C
authors.initials: C
authors.lastname: Nucera
authors.forename: G
authors.initials: G
authors.lastname: Pellegriti
authors.forename: P
authors.initials: P
authors.lastname: Gangemi
authors.forename: M
authors.initials: M
authors.lastname: Attard
authors.forename: M
authors.initials: M
authors.lastname: Stella
authors.forename: M
authors.initials: M
authors.lastname: Loda
authors.forename: V
authors.initials: V
authors.lastname: Vella
authors.forename: C
authors.initials: C
authors.lastname: Giordano
authors.forename: F
authors.initials: F
authors.lastname: Trimarchi
authors.forename: E
authors.initials: E
authors.lastname: Mazzon
authors.forename: A
authors.initials: A
authors.lastname: Belfiore
authors.forename: R
authors.initials: R
authors.lastname: Vigneri
mesh_terms: D002291:Carcinoma, Papillary / Q000235:genetics*; D017931:DNA Primers; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005843:Geography; D006801:Humans; D007124:Immunoenzyme Techniques; D007834:Lasers; D008207:Lymphatic Metastasis; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D042282:Microdissection; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009361:Neoplasm Invasiveness; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012802:Sicily / Q000453:epidemiology; D013964:Thyroid Neoplasms / Q000235:genetics*
chemical_list: D017931:DNA Primers; D012333:RNA, Messenger; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020780:Matrix Metalloproteinase 9